Europe Over The Counter Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product Category (Cold, Cough, And Flu Products, Analgesic, Dermatology Products, Gastrointestinal Products, Vitamin, Minerals, And Supplements, Weight Loss And Dietary Products, Ophthalmic Products, Sleep Aids, Others), By Administration (Oral, Topical, Nasal, And Others), And By Geography - Forecasts From 2021 To 2026

  • Published : Jul 2021
  • Report Code : KSI061611053
  • Pages : 114

Europe over the counter (OTC) drug market is projected to grow at a CAGR of 4.19% during the forecast period to reach US$55.238 billion by 2026, from US$41.454 billion in 2019. Increasing health consciousness coupled with a surge in medical expenditure for better health is driving the market growth of the European OTC drug industry. Particularly, in Germany and France, a rise in health expenditure for longer and healthier life in supporting the market growth. Furthermore, the increasing proportion of the geriatric population in the region has significantly escalated the demand for necessary drugs, driving considerable market growth. However, the emergence of e-commerce in the drug industry and the surging popularity of drug aggregates that deliver drugs at the patient’s doorstep are hindering market growth.

The increasing proportion of the geriatric population in the overall regional demography is escalating the demand for necessary drugs that are anticipated to increase the market growth of OTC drugs during the forecasted period.

One of the prime reasons that are supporting the market growth of OTC drugs in Europe is the increasing proportion of the geriatric population who require necessary drugs for better health. Italy, Greece, France, and Germany are facing a significant change in the population demography with a notable rise in the proportion of aged people. In Italy, the population above 65 years of age has increased from 12.108 million in 2010 to 13.887 million in 2020. The proportion increased from 20.42% in 2010 to 23.03% in 2020, hence making the country economy with the highest proportion of the aged population in the European region. Globally, Italy stands at the second position, after Japan, under the category of a proportion of the population aged 65 years and above. In Greece, this age group has increased from 2.129 million in 2010 to 2.387 million in 2020 i.e. to 22.28% from 19.1% in 2010. Germany, France, and Spain also saw a significant rise in aged population. The growing aged population has substantially increased the demand for drugs which is anticipated to provide a significant scope and growth opportunity for the market.

The rising penetration of e-commerce and inculcation of robotics in drug delivery services is projected to drive away a significant share of the market and hence hinder the market growth.

The European OTC drug market is threatened considerably by increasing penetration of e-commerce and inculcation of robots’ delivery in drug delivery services, which has the potential to notably decrease the market share of OTC drug sales. Increased investment in automation and convenience services is supporting the market growth of drug delivery services, hindering the growth of the OTC drug market.

Covid Insights.

The coronavirus pandemic significantly increased the market for OTC drugs in the European region. With the outbreak of the virus, demand for necessary drugs surged, especially, for cold, cough, and flu, vitamin, minerals, and supplements, and cardiovascular diseases, supporting the market growth.

Europe Over the Counter Drug Market Scope:

Report Metric Details
 Market size value in 2019  US$41.454 billion
 Market size value in 2026  US$55.238 billion
 Growth Rate  CAGR of 4.19% from 2019 to 2026
 Base year  2019
 Forecast period  2021–2026
 Forecast Unit (Value)  USD Billion
 Segments covered  Product Category, Administration, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Novartis AG, Sanofi, Cardinal Health, Bayer AG, Johnson & Johnson, Pfizer,   GlaxoSmithKline plc, Stada Arzeimittel AG, Viatris Inc.
 Customization scope  Free report customization with purchase


Key Market Segments

  • By Product Category
    • Cold, Cough, and Flu Products
    • Analgesic
    • Dermatology products
    • Gastrointestinal Products
    • Vitamin, Minerals, and Supplements
    • Weight loss and Dietary Products
    • Ophthalmic Products
    • Sleep Aids
    • Others
  • By Administration
    • Oral
    • Topical, Nasal, and others
  • By Geography
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Others

1.1. Market Definition
1.2. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Cold, Cough, and Flu Products
5.3. Analgesic
5.4. Dermatology products
5.5. Gastrointestinal Products
5.6. Vitamin, Minerals, and Supplements
5.7. Weight loss and Dietary Products
5.8. Ophthalmic Products
5.9. Sleep Aids
5.10. Others  
6.1. Introduction
6.2. Oral
6.3. Topical, Nasal, and Others

7.1. Introduction
7.2. Germany
7.3. France
7.4. United Kingdom 
7.5. Spain 
7.6. Others

8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9. Company Profiles
9.1. Novartis AG
9.2. Sanofi
9.3. Cardinal Health
9.4. Bayer AG
9.5. Johnson & Johnson
9.6. Pfizer
9.7. GlaxoSmithKline plc
9.8. Stada Arzeimittel AG
9.9. Viatris Inc. 

Novartis AG


Cardinal Health

Bayer AG

Johnson & Johnson


GlaxoSmithKline plc

Stada Arzeimittel AG

Viatris Inc.